Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice

Abstract

BACKGROUND: Although there is no doubt that bisphosphonates (BPs), specific inhibitors of osteoclasts, are beneficial for the treatment of bone metastases, their effects on visceral metastases are unclear. The effect of zoledronic acid (ZOL) was examined in vivo on lung metastasis progression and animal survival, and in vitro on the cellular mechanisms involved. METHODS: An animal model of lung metastasis was developed in C3H/He mice inoculated intravenously with a spontaneous murine osteosarcoma POS‐1 cell line. Lung metastasis was determined at the time of autopsy. ZOL was assessed in vitro on POS‐1 cell proliferation, cell cycle progression, and caspase‐1 and ‐3 activities. RESULTS: The overall survival in five independent experiments (two series treated with ZOL 0.1 mg/kg twice a week, and three series with 0.1 mg/kg five times a week) showed a significant increase of the actuarial survival: 0.422 ± 0.07 in ZOL‐treated animals versus 0.167 ± 0.07 in controls (P = 0.036). Lung metastases were absent in all ZOL‐treated mice that survived more than 21 days postinjection as revealed by macroscopic and histologic analysis. In vitro, a 48‐hour incubation with 10 μM ZOL inhibited POS‐1 cell line proliferation associated with cell cycle arrest in S‐phase. In addition, ZOL induced a weak increase of caspase‐3 activity, but not caspase‐1. CONCLUSION: We demonstrate that ZOL exerts a direct antitumor effect on POS‐1 cells in vitro, significantly diminishes osteosarcoma‐induced lung metastasis in vivo, thereby prolonging survival of POS‐1‐inoculated animals. Cancer 2005. © 2005 American Cancer Society.